Skip to main content

Articles

Page 3 of 66

  1. Mounting evidence suggests a strong association between tumor immunity and epigenetic regulation. The histone-lysine N-methyltransferase 2 (KMT2) family plays a crucial role in the methylation of histone H3 at...

    Authors: Dong-Xu Wang, Jun-Yu Long, Rui-Zhe Li, Dao-Lin Zhang, Hui Liu, Jingru Liu, Jin-Cheng Tian, Han Li, Jie Liu, Hai-Tao Zhao and Tao Li
    Citation: Molecular Cancer 2024 23:15
  2. The tumor microenvironment (TME) is an intricate system comprised of tumor cells and the surrounding cellular and non-cellular components, exerting a pivotal influence on the initiation and progression of tumo...

    Authors: Xinming Su, Chenhao Liang, Ruixiu Chen and Shiwei Duan
    Citation: Molecular Cancer 2024 23:13
  3. Malignant peritoneal mesothelioma (MPM) is an extremely rare and highly invasive tumor. Due to the lack of accurate models that reflect the biological characteristics of primary tumors, studying MPM remains ch...

    Authors: XiaoChang Fang, Lin Shu, TianLiang Chen, XiaoLe Zhao, LiuCui Yang, Tingting Dou, Lijie Yang, Xuanfei Li and Maohui Feng
    Citation: Molecular Cancer 2024 23:12
  4. Dysregulation of R-loop homeostasis is closely related to various human diseases, including cancer. However, the causality of aberrant R-loops in tumor progression remains unclear. In this study, using single-...

    Authors: Shichao Zhang, Yang Liu, Yichi Sun, Qin Liu, Yan Gu, Ya Huang, Zhu Zeng, Fuzhou Tang and Yan Ouyang
    Citation: Molecular Cancer 2024 23:11
  5. This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx).

    Authors: Tim Schmäche, Juliane Fohgrub, Anna Klimova, Karin Laaber, Stephan Drukewitz, Felix Merboth, Alexander Hennig, Therese Seidlitz, Friederike Herbst, Franziska Baenke, Anne-Marlen Ada, Thomas Groß, Carina Wenzel, Claudia R. Ball, Christian Praetorius, Thomas Schmidt…
    Citation: Molecular Cancer 2024 23:10
  6. The CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize the field of cancer research and therapy. The ability to precisely target and edit specific genetic mutations th...

    Authors: Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian-Ghahfarokhi, Marjan Shafieizadeh, Esmaeil Mahmoudi, Fatemeh Eskandari, Mohsen Rashidi, Asghar Arshi and Abbas Mokhtari-Farsani
    Citation: Molecular Cancer 2024 23:9

    The Correction to this article has been published in Molecular Cancer 2024 23:43

  7. Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunothe...

    Authors: Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, Najla Santos Pacheco de Campos, Rabia Abbas, Renata Schmieder Pivetta, Nithyassree Murugan, Ghanbar Mahmoodi Chalbatani, Vincent D’Andrea and Wayne A. Marasco
    Citation: Molecular Cancer 2024 23:8
  8. In the early 1990’s a group of unrelated genes were identified from the sites of recurring translocations in B-cell lymphomas. Despite sharing the nomenclature ‘Bcl’, and an association with blood-borne cancer...

    Authors: Gillian Seaton, Hannah Smith, Andrea Brancale, Andrew D. Westwell and Richard Clarkson
    Citation: Molecular Cancer 2024 23:7
  9. Adoptive cell transfer cancer immunotherapy holds promise for treating disseminated disease, yet generating sufficient numbers of lymphocytes with anti-cancer activity against diverse specificities remains a m...

    Authors: Odd L. Gammelgaard, Mikkel G. Terp, Alexei F. Kirkin, Simone Johansen, Sofie Traynor, Henriette Vever, Per Guldberg, Annette R. Kodahl, Morten F. Gjerstorff and Henrik J. Ditzel
    Citation: Molecular Cancer 2024 23:6
  10. Cisplatin (CDDP) is the first-line chemotherapeutic strategy to treat patients with ovarian cancer (OC). The development of CDDP resistance remains an unsurmountable obstacle in OC treatment and frequently ind...

    Authors: Han Li, Run Lin, Yanna Zhang, Yanni Zhu, Shuting Huang, Jing Lan, Nian Lu, Chuanmiao Xie, Shanyang He and Weijing Zhang
    Citation: Molecular Cancer 2024 23:5
  11. Renal cell carcinoma (RCC) is one of the most common malignant tumor worldwide. Metastasis is a leading case of cancer-related deaths of RCC. Circular RNAs (circRNAs), a class of noncoding RNAs, have emerged a...

    Authors: Zaosong Zheng, Xiangbo Zeng, Yuanchao Zhu, Mengxin Leng, Zhiyong Zhang, Qiong Wang, Xiaocen Liu, Siying Zeng, Yongyuan Xiao, Chenxi Hu, Shiyu Pang, Tong Wang, Bihong Xu, Peidan Peng, Fei Li and Wanlong Tan
    Citation: Molecular Cancer 2024 23:4
  12. Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less adv...

    Authors: Yunpeng Luan, Xiang Li, Yunqi Luan, Junyu Luo, Qinzuo Dong, Shili Ye, Yuejin Li, Yanmei Li, Lu Jia, Jun Yang and Dong-Hua Yang
    Citation: Molecular Cancer 2024 23:2
  13. This study investigates methylation patterns in circulating cell-free DNA (ccfDNA) for their potential role in colorectal cancer (CRC) detection and the monitoring of treatment response. Through methylation mi...

    Authors: Kazuya Yasui, Toshiaki Toshima, Ryo Inada, Yuzo Umeda, Shuya Yano, Hiroaki Tanioka, Akihiro Nyuya, Toshiyoshi Fujiwara, Takeshi Yamada, Yoshio Naomoto, Ajay Goel and Takeshi Nagasaka
    Citation: Molecular Cancer 2024 23:1
  14. Immune checkpoint inhibitors have revolutionized cancer therapy, yet the efficacy of these treatments is often limited by the heterogeneous and hypoxic tumor microenvironment (TME) of solid tumors. In the TME,...

    Authors: Philipp Knopf, Dimitri Stowbur, Sabrina H. L. Hoffmann, Natalie Hermann, Andreas Maurer, Valentina Bucher, Marilena Poxleitner, Bredi Tako, Dominik Sonanini, Balaji Krishnamachary, Sanhita Sinharay, Birgit Fehrenbacher, Irene Gonzalez-Menendez, Felix Reckmann, David Bomze, Lukas Flatz…
    Citation: Molecular Cancer 2023 22:207
  15. Social behaviors such as altruism, where one self-sacrifices for collective benefits, critically influence an organism’s survival and responses to the environment. Such behaviors are widely exemplified in natu...

    Authors: Muhammad Sufyan Bin Masroni, Kee Wah Lee, Victor Kwan Min Lee, Siok Bian Ng, Chao Teng Law, Kok Siong Poon, Bernett Teck-Kwong Lee, Zhehao Liu, Yuen Peng Tan, Wee Ling Chng, Steven Tucker, Lynette Su-Mien Ngo, George Wai Cheong Yip, Min En Nga, Susan Swee Shan Hue, Thomas Choudary Putti…
    Citation: Molecular Cancer 2023 22:206
  16. Targeted drugs are not quite effective for prolonging the survival of patients with gastric cancer due to off-target effects as well as tumor immune escape mechanisms. Circular RNAs widely exist in tumor regio...

    Authors: Zhenyan Miao, Jifei Li, Yu Wang, Mingqin Shi, Xiao Gu, Xuanqi Zhang, Fang Wei, Xinying Tang, Lufeng Zheng and Yingying Xing
    Citation: Molecular Cancer 2023 22:205
  17. Lung squamous cell carcinoma (LUSC) is associated with high mortality and limited targeted therapies. USP13 is one of the most amplified genes in LUSC, yet its role in lung cancer is largely unknown. Here, we ...

    Authors: Juntae Kwon, Jinmin Zhang, Boram Mok, Samuel Allsup, Chul Kim, Jeffrey Toretsky and Cecil Han
    Citation: Molecular Cancer 2023 22:204
  18. Tumor immunotherapy has transformed neoplastic disease management, yet low response rates and immune complications persist as major challenges. Extracellular vesicles including exosomes have emerged as therape...

    Authors: Ming Yue, Shengyun Hu, Haifeng Sun, Baojing Tuo, Bin Jia, Chen Chen, Wenkang Wang, Jinbo Liu, Yang Liu, Zhenqiang Sun and Junhong Hu
    Citation: Molecular Cancer 2023 22:203
  19. Liver metastasis is the leading cause of death in patients with colorectal cancer (CRC). Emerge evidence suggests that circular RNA (circRNA) is a pivotal player in cancer progression. However, its role in CRC...

    Authors: Kaixuan Zeng, Jianhong Peng, Yue Xing, Linjie Zhang, Peishan Zeng, Weihao Li, Weili Zhang, Zhizhong Pan, Chi Zhou and Junzhong Lin
    Citation: Molecular Cancer 2023 22:202
  20. Autophagy is an essential cellular homeostasis pathway initiated by multiple stimuli ranging from nutrient deprivation to viral infection, playing a key role in human health and disease. At present, a growing ...

    Authors: Manuela Giansanti, Tobias Theinert, Sarah Katharina Boeing, Dorothee Haas, Paul-Gerhardt Schlegel, Paola Vacca, Francesca Nazio and Ignazio Caruana
    Citation: Molecular Cancer 2023 22:201
  21. Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contri...

    Authors: Yunlin Zhang, Ruchi P. Patel, Ki Hyun Kim, Hyungwoo Cho, Jae-Cheol Jo, Seong Hyun Jeong, Sung Yong Oh, Yoon Seok Choi, Sung Hyun Kim, Ji Hyun Lee, Mathew Angelos, Puneeth Guruprasad, Ivan Cohen, Ositadimma Ugwuanyi, Yong Gu Lee, Raymone Pajarillo…
    Citation: Molecular Cancer 2023 22:200
  22. Colorectal cancer (CRC) is one of the most threatening tumors in the world, and chemotherapy remains dominant in the treatment of metastatic CRC (mCRC) patients. The purpose of this study was to develop a biom...

    Authors: Ya’nan Yang, Jieyun Zhang, Wen Zhang, Yixuan Wang, Yujia Zhai, Yan Li, Wenhua Li, Jinjia Chang, Xiaoying Zhao, Mingzhu Huang, Qirong Geng, Yue Yang, Zhe Gong, Nuoya Yu, Wei Shen, Qian Li…
    Citation: Molecular Cancer 2023 22:199
  23. Tumor angiogenesis plays vital roles in the growth and metastasis of cancer. RNA methylation is one of the most common modifications and is widely observed in eukaryotes and prokaryotes. Accumulating studies h...

    Authors: Mingyu Han, Haifeng Sun, Quanbo Zhou, Jinbo Liu, Junhong Hu, Weitang Yuan and Zhenqiang Sun
    Citation: Molecular Cancer 2023 22:198
  24. Hepatocellular carcinoma (HCC), one of the most prevalent forms of cancer worldwide, presents a significant global healthcare challenge. Cancer stem cells (CSCs), which can influence neighboring non-CSCs, are ...

    Authors: Tao Han, Lujun Chen, Kerui Li, Qilin Hu, Yue Zhang, Xuan You, Lei Han, Tingsong Chen and Kai Li
    Citation: Molecular Cancer 2023 22:197
  25. Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents. Th...

    Authors: Nuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M. Schnoeder, Theresa Eifert, Chen-Jen Hsu, Florian Perner, Qirui Zhang, Daniela V. Wenge, Fynn M. Hansen, Joanna M. Kirkpatrick, Nidhi Jyotsana, Steven W. Lane, Björn von Eyss, Aniruddha J. Deshpande, Michael W. M. Kühn, Juerg Schwaller…
    Citation: Molecular Cancer 2023 22:196
  26. Circular RNAs (circRNAs) play important roles in the occurrence and development of cancer and chemoresistance. DNA damage repair contributes to the proliferation of cancer cells and resistance to chemotherapy-...

    Authors: Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren and Pengbo Zhang
    Citation: Molecular Cancer 2023 22:195

    The Correction to this article has been published in Molecular Cancer 2024 23:16

  27. Current research has demonstrated that extracellular vesicles (EVs) and circulating tumor cells (CTCs) are very closely related in the process of distant tumor metastasis. Primary tumors are shed and released ...

    Authors: Siyin Guo, Jing Huang, Genpeng Li, Wenjie Chen, Zhihui Li and Jianyong Lei
    Citation: Molecular Cancer 2023 22:193
  28. Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the...

    Authors: Andrea Sacconi, Paola Muti, Claudio Pulito, Giulia Urbani, Matteo Allegretti, Raul Pellini, Nikolay Mehterov, Uri Ben-David, Sabrina Strano, Paolo Bossi and Giovanni Blandino
    Citation: Molecular Cancer 2023 22:192
  29. Despite major improvements in immunotherapeutic strategies, the immunosuppressive tumor microenvironment remains a major obstacle for the induction of efficient antitumor responses. In this study, we show that...

    Authors: Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uzé, Niko Kley, Anje Cauwels and Jan Tavernier
    Citation: Molecular Cancer 2023 22:191
  30. Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matr...

    Authors: Pere Llinàs-Arias, Miquel Ensenyat-Mendez, Sandra Íñiguez-Muñoz, Javier I. J. Orozco, Betsy Valdez, Matthew P. Salomon, Chikako Matsuba, Maria Solivellas-Pieras, Andrés F. Bedoya-López, Borja Sesé, Anja Mezger, Mattias Ormestad, Fernando Unzueta, Siri H. Strand, Alexander D. Boiko, E Shelley Hwang…
    Citation: Molecular Cancer 2023 22:190
  31. The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenc...

    Authors: Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, Hamidreza Kabiri, Hosein Salehian-Dehkordi, Mohammad Abdolvand, Sharareh Salmanizadeh, Mohsen Rashidi, Anoosha Niazmand, Saba Ahmadi, Sara Feizbakhshan, Saber Kabiri, Nasimeh Vatandoost and Tayebeh Ranjbarnejad
    Citation: Molecular Cancer 2023 22:189
  32. Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosup...

    Authors: Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai and Kongming Wu
    Citation: Molecular Cancer 2023 22:187
  33. Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).

    Authors: Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai…
    Citation: Molecular Cancer 2023 22:185
  34. Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Angiogenesis is a main contributing factor for tumorigenesis. E74-like transcription factor 5 (ELF5) has been verified to participa...

    Authors: Tushuai Li, Longjiang Xu, Zhe Wei, Shaomei Zhang, Xingyu Liu, Yanzi Yang, Yue Gu and Jie Zhang
    Citation: Molecular Cancer 2023 22:184
  35. Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors...

    Authors: Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown and Hamid Reza Mirzaei
    Citation: Molecular Cancer 2023 22:183
  36. Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivoluma...

    Authors: Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu…
    Citation: Molecular Cancer 2023 22:182
  37. The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detecti...

    Authors: Nikolas H. Stoecklein, Georg Fluegen, Rosa Guglielmi, Rui P.L. Neves, Thilo Hackert, Emrullah Birgin, Stefan A. Cieslik, Monica Sudarsanam, Christiane Driemel, Guus van Dalum, André Franken, Dieter Niederacher, Hans Neubauer, Tanja Fehm, Jutta M. Rox, Petra Böhme…
    Citation: Molecular Cancer 2023 22:181
  38. Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in failure of normal hematopoiesis a...

    Authors: Tatjana Sauerer, Giuliano Filippini Velázquez and Christoph Schmid
    Citation: Molecular Cancer 2023 22:180
  39. Noncoding RNAs such as circular RNAs (circRNAs) are abundant in the human body and influence the occurrence and development of various diseases. Non-small cell lung cancer (NSCLC) is one of the most common mal...

    Authors: Yumeng Cui, Xiaojie Wu, Jie Jin, Weiling Man, Jie Li, Xiang Li, Yanghua Li, He Yao, Rongbin Zhong, Shiyun Chen, Jiahui Wu, Tianhao Zhu, Yanli Lin, Junjie Xu and Youliang Wang
    Citation: Molecular Cancer 2023 22:179
  40. Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instabi...

    Authors: Cyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, Damien Vasseur, Audrey Le Formal, Laure Chardin, Elisa Yaniz, Sébastien Gouy, Amandine Maulard, Stéphanie Scherier, Claire Sanson, Ludovic Lacroix, Sophie Cotteret, Lea Mauny, François Zaccarini, Etienne Rouleau…
    Citation: Molecular Cancer 2023 22:178
  41. Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remain...

    Authors: Ji Eun Shin, Soo-Hyun Kim, Mingyu Kong, Hwa-Ryeon Kim, Sungmin Yoon, Kyung-Mi Kee, Jung Ah Kim, Dong Hyeon Kim, So Yeon Park, Jae Hyung Park, Hongtae Kim, Kyoung Tai No, Han-Woong Lee, Heon Yung Gee, Seunghee Hong, Kun-Liang Guan…
    Citation: Molecular Cancer 2023 22:177
  42. Despite the effectiveness of the various targeted therapies currently approved for solid tumors, acquired resistance remains a persistent problem that limits the ultimate effectiveness of these treatments. Pol...

    Authors: Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, Mariella Spalato-Ceruso, Mihaela Aldea, Damien Vasseur, Melissa Alame, Laura Blouin, Isabelle Soubeyran, Claudio Nicotra, Maud Ngocamus, Antoine Hollebecque, Yohann Loriot, Benjamin Besse…
    Citation: Molecular Cancer 2023 22:176

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions